recombinant human endostatin

Recombinant human endostatin is a genetically engineered form of the endogenous protein endostatin, which is a 20 kDa C-terminal fragment derived from type XVIII collagen. It functions as a broad-spectrum angiogenesis inhibitor by inducing apoptosis in microvascular endothelial cells and inhibiting their proliferation and migration. The primary mechanism involves inhibition of vascular endothelial growth factor (VEGF) signaling, particularly through VEGF receptor 2 (KDR/Flk1), leading to reduced tumor neovascularization and growth. Additional mechanisms include blocking activation of extracellular signal-regulated kinases (ERK), p38 mitogen activated protein kinase (MAPK), focal adhesion kinase, E-selectin activity, and matrix metalloproteinases 2, 9, and 13. Recombinant human endostatin has been approved in China since 2006 for non-small cell lung cancer under the brand name Endostar and continues to be investigated for other malignancies[1][2][3][4][8].

Brand names

Endostar

Other names

endostatinrecombinant human endostatinantiangiogenic agentcollagen alpha-1(XVIII) chain fragment